Combination drug therapy for dyslipidemia

Current Atherosclerosis Reports

Volumn 1, Issue 1, 1999, Pages 44-49

  Alaswad, Khaldoon ^a   O’Keefe, James H ^a   Moe, Richard M ^a  

^a Mid America Heart Institute at Saint Luke's Hospital   (United States)

Author keywords

Lovastatin; Niacin; Pravastatin; Statin; Statin Therapy

Indexed keywords

ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SITOSTEROL DERIVATIVE;

BLOOD; DRUG COMBINATION; HUMAN; HYPERLIPIDEMIA; REVIEW;

ANION EXCHANGE RESINS; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FISH OILS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; NIACIN; SITOSTEROLS;

EID: 0033156991     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-999-0049-z     Document Type: Article

References (43)

1. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357. DOI: 10.1056/NEJM199811053391902
2. Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995, 345:1274–1275.
3. Shepard J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307. DOI: 10.1056/NEJM199511163332001
4. Downs Jr, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622. DOI: 10.1001/jama.279.20.1615
5. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009. DOI: 10.1056/NEJM199610033351401
6. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89:1329–1445.
7. Hoerger TJ, Bala Mohan, Bray JW, et al.: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol. 1998, 82:61–65. DOI: 10.1016/S0002-9149(98)00227-6
8. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anti-coagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997, 336:153–62. DOI: 10.1056/NEJM199701163360301
9. Brown AS, Anderson TJ, Pitt B, et al.: AVERT Study: Oral Presentation. November 11, 1998. American Heart Association Annual Scientific Sessions. JAMA August 1999, in press.
10. Jones P, Kafonek S, Laurora I, et al.: Comarative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998, 81:582–587. DOI: 10.1016/S0002-9149(97)00965-X
11. O’Keefe JH, Miles JM, Harris WH, et al.: Improving the adverse cardiovascular prognosis of Type 2 diabetes. Mayo Clin Proc 1999, 74:171–180. DOI: 10.4065/74.2.171
12. Jeppesen J, Ole Hein H, Suadicani P, et al.: Triglyceride concentration and ischemic heart disease: An eight year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029–1036.
13. Miller M, Sideler A, Moealemi A, et al.: Normal trigylceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study. JACC 1998, 31:1252–1257.
14. Gaziano JM, Hennekens CH, O’Donnell CJ, et al.: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997, 96:2520–2525.
15. O’Keefe JH, Harris WS, Nelson J, et al.: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995, 76:480–484. DOI: 10.1016/S0002-9149(99)80134-9
16. Davignon J, Roederer G, Montigny M, et al.: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994, 73:339–345. DOI: 10.1016/0002-9149(94)90005-1
17. Gardner SF, Marx MA, White LM, et al.: Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother 1997, 31:677–682.
18. Gardner SF, Schneider EF, Granberry MC, et al.: Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996, 16:419–423.
19. Tsalamandris C, Panagiotopoulos S, Sinha A, et al.: Complementary effects of pravastatin and nicotonic acid in the treatment of combined hyperlipidemia in diabetic and nondiabetic patients. J Cardiovasc Risk 1994, 1:231–239.
20. Reaven P, Witztum JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Anna Intern Med 1988, October: 597–598.
21. McKenney JM, Proctor JD, Harris S, et al.: A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994, 271:672–677. DOI: 10.1001/jama.271.9.672
22. Knopp RH, Alogona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097–1104. DOI: 10.1016/S0026-0495(98)90284-0
23. Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesteremia. Am J Cardiol 1998, 82:737–743. DOI: 10.1016/S0002-9149(98)00448-2
24. Canner PL, Berge K, Wenger NK, et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255. DOI: 10.1016/S0735-1097(86)80293-5
25. Cardlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418. DOI: 10.1111/j.0954-6820.1988.tb15891.x
26. Brown BG, Sacco D, Zhao X-Q, et al.: Lipid-lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993, 87:1781–1791.
27. O’Keefe JH, Harris WS: Nicotinic acid-the underused ally in the fight against coronary disease. J Cardiovasc Risk 1997, 4:161–163. DOI: 10.1097/00043798-199706000-00001
28. Miller M, Vogel RA: The practice of coronary disease prevention. In Total and Low-Density Lipoprotein Cholesterol. Edited by Retford DC, Kiehne Hayes LA; Philadelphia: William and Wilkins; 1996:50–52.
29. GelTex Pharmaceuticals, Inc.: Cholestagel. March 15, 1999, in press.
30. Schetman G, Hiatt J, Hartz A: Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Card 1993, 71:759–765. DOI: 10.1016/0002-9149(93)90820-3
31. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk-factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237–1245. DOI: 10.1056/NEJM198711123172001
32. Gould AL, Rossouq JE, Santanello NC, et al.: Cholesterol reduction yields clinical benefit. Circulation 1995, 91:2274–2282.
33. Glueck CJ, Oakes N, Speirs J, et al.: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992, 70:1–9. DOI: 10.1016/0002-9149(92)91380-M
34. Pierce LR, Wysowski DK, Gross TP: Myocpathy and rhabdomyalysis assoicated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71–5. DOI: 10.1001/jama.264.1.71
35. Albert CM, Hennekens CH, O’Donnell CJ, et al.: Fish consumption and risk of sudden cardiac death. JAMA 1998, 279:23–28. DOI: 10.1001/jama.279.1.23
36. Siscovick DS, Raghunathan TE, King I, et al.: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995, 274:1363–1367. DOI: 10.1001/jama.274.17.1363
37. Marchioli R: Efficacy of n-3 PUFA and vitamin E in 11,324 post-MI patients: Results of GISSI-Prevenzione. Lancet 1999, in press.
38. Harris WS: n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65 (suppl):1645–1654.
39. Nordoy A, Bonaa KH, Nilsen H, et al.: Effects of simvastatin and omega-3 fatty acids in plasma lipoproteins and lipid peroxidation in patiens with combined hyperlipidaemia. J Int Med 1998, 243:163–170. DOI: 10.1046/j.1365-2796.1998.00297.x
40. Contacos C, Barter PJ, Sullivan DR: Effect of pravastatin and w-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993, 13:1755–1762.
41. Hansen JB, Lyngmo V, Svensson B, et al.: Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia. Arterioscler Thromb 1993, 1:98–104.
42. Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995, 333:1308–1312. DOI: 10.1056/NEJM199511163332002
43. Gylling H, Miettinen TA: Sitostanol ester added to long-term simvastatin treatment of coronary patients with low and high basal cholesterol absorption. J Am Coll Cardiol 1998, 31 (Suppl):281. DOI: 10.1016/S0735-1097(98)81867-6